EM1708G "Primary Biliary Cholangitis/Cirrhosis” (IM GR-081117)
  • To improve clinical management of patients with PBC
  • To show physicians and scientists how recent advances in our understanding of bile acid metabolism and inflammation may be relevant to the pathogenesis of PBC and may lead to new therapies

Download Protocol

Course details

  • AMA PRA Category 1 Credit™: 1.00
  • Course opens: Wed, Aug 16 2017
  • Course expires: Fri, Sep 15 2017
  • Cost: $0.00

Target audience

UT Southwestern faculty, fellows, residents and medical students, community physicians, nurse clinicians, physician assistants and nurses.

Learning objectives

At the conclusion of this activity, the participant should be able to:

  • Recall the new name for primary biliary cirrhosis of “primary biliary cholangitis” and understand why the name was changed
  • Recognize the full spectrum of clinical presentation of PBC
  • Know the two FDA-approved therapies for PBC, and their mechanism of action

Faculty & credentials

Photo: Marlyn J. Mayo, M.D. Marlyn J. Mayo, M.D.
Associate Professor of Medicine
Division of Digestive & Liver Diseases

Required hardware / software

Activities should be run with recent versions of common browsers, including Internet Explorer, Firefox and Google Chrome

This activity closed on September 15th, 2017 and is no longer available for enrollments.